A Phase III, Randomized, Double-Blind Comparison of Oral Valganciclovir and Placebo for Prevention of CMV After Lung Transplantation

Trial Profile

A Phase III, Randomized, Double-Blind Comparison of Oral Valganciclovir and Placebo for Prevention of CMV After Lung Transplantation

Completed
Phase of Trial: Phase III

Latest Information Update: 26 Apr 2013

At a glance

  • Drugs Valganciclovir (Primary)
  • Indications Cytomegalic inclusion disorders
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Most Recent Events

    • 01 Aug 2011 Actual end date (December 2008) added as reported by ClinicalTrials.gov.
    • 15 Jun 2010 Primary endpoint 'CMV end-organ disease and CMV clinical syndrome' has been met, according to an article published in Annals of Internal Medicine
    • 15 Jun 2010 Status changed from active, no longer recruiting to completed, according to an article published in Annals of Internal Medicine.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top